Compound News and Research

RSS

Calibr-Skaggs and Kainomyx join forces to accelerate development of antimalarial drugs

The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research and Kainomyx, Inc., today announced a new research collaboration to accelerate the discovery and development of next-generation antimalarial drugs.

17 Feb 2026

Bioengineered E. coli bacteria can now produce rhododendron-derived drugs

Bioengineered E. coli bacteria can now produce a group of compounds with anticancer, anti-HIV, antidiabetic and anti-inflammatory activities.

17 Feb 2026

Synergistic drug pair shows promise for spinal cord injury recovery

Spinal cord injury remains one of the most challenging neurological conditions to treat, largely because damage continues to worsen long after the initial trauma.

16 Feb 2026

Innate immune priming may evolve into a broadly applicable infection-prevention strategy

Secondary infections caused by bacteria or viruses during hospital care remain a long-standing global challenge, despite advances in modern medicine.

16 Feb 2026

Role of food nutrients in reducing oxidative stress linked to micro- and nanoplastics

This narrative review examines how micro- and nanoplastics may contribute to oxidative stress, inflammation, and metabolic dysfunction, including potential links with diabetes. It highlights plant-derived nutrients that activate the Nrf2 pathway as a possible strategy to enhance cellular stress resilience, although most evidence remains preclinical.

15 Feb 2026

Modified peptides show promise against tuberculosis bacteria

Antibiotic treatments are losing effectiveness against a range of common bacterial pathogens, including E. coli, K. pneumoniae, Salmonella and Acinetobacter, according to a warning issued by the World Health Organization last October.

13 Feb 2026

Thermodynamic insights into histamine H1 receptor ligand binding

G-protein-coupled receptors (GPCRs) are one of the largest families of cell surface proteins in the human body that recognize hormones, neurotransmitters, and drugs.

13 Feb 2026

Tiny organism offers insight into neurological side effects of chemotherapy

Chemotherapy remains one of the most powerful tools in the fight against cancer, yet it often comes with significant long-term side effects that can dramatically affect patients' quality of life.

11 Feb 2026

Review links betel nut addiction to cancer, heart disease, and metabolic risks

This review examines the epidemiology, health risks, neurobiological mechanisms, and emerging treatments related to betel nut addiction worldwide. It highlights strong links with oral cancer, cardiometabolic disease, and addiction pathways while noting limited established therapies and the need for coordinated public health strategies.

11 Feb 2026

Dual targeting strategy suppresses pancreatic cancer cell growth

A new research paper was published in Volume 13 of Oncoscience on January 28, 2026, titled "Dual targeting of oncogenic microtubules and mitochondria in PDAC."

10 Feb 2026

Tumor-targeted chimeric drug increases efficacy and limits side effects

Wistar scientists have combined a promising cancer therapy with a molecule that targets tumors to treat cancer more effectively.

7 Feb 2026

Study reveals what drives PFAS exposure in firefighters and how risks may be reduced

A large U.S. firefighter cohort study identified personal, occupational, and department-level predictors of serum PFAS concentrations, highlighting both modifiable exposures and persistent background sources. Some protective practices, blood or plasma donation, and drinking water sources were associated with differences in specific PFAS analytes, although causal relationships require further longitudinal study.

4 Feb 2026

Small molecule targets glioblastoma oncogene in preclinical studies

UVA Comprehensive Cancer Center scientists have identified a molecule that blocks the gene responsible for glioblastoma, raising hopes that the molecule could become a much-needed new treatment for the deadliest brain cancer.

4 Feb 2026

New compound advances body clock independent of dosing time

A collaborative team including Emeritus Professor Tei H. (Kanazawa University), Associate Professor Takahata Y. (Osaka University), Professor Numano R. (Toyohashi University of Technology), and Associate Professor Uriu K. (Institute of Science Tokyo) discovered that Mic-628 selectively induces the mammalian clock gene Per1.

4 Feb 2026